InflaRx treats first pyoderma gangraenosum patient in Phase 2a trial

InflaRx (NASDAQ:IFRX) treated the first patient in a Phase 2a trial of IFX-1, an injectable antibody drug, in pyoderma gangraenosum (PG) patients.

PG is a rare autoinflammatory disease, characterized by acute skin ulceration, primarily on the legs. IFX-1 is a monoclonal anti-human complement factor C5a antibody designed to control the inflammatory response.

“PG is a debilitating disease with limited treatment options,” Dr. Afsaneh Alavi, the trial’s principal investigator, said in a statement.

“A high medical need exists to develop new treatments, especially ones with novel modes of action,” he added.

The trial plans to enroll some 12 PG patients to evaluate the safety and efficacy of IFX-1, the latter of which will be determined by ulcer response rate.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.